Fig 1: Increased galectin-1 expression in the liver of mice fed with a high fat diet (HFD) and obese mice. (A) Comparison of galectin-1 mRNA levels in livers of controls (n = 6) and HFD fed mice (n = 6) and ob/ob mice (n = 6). (B) Representative Western blots and relative protein expression of total liver lysates from controls (n = 6) and mice fed with HFD (n = 6) and ob/ob mice (n = 6). Data represent the means ± SEM; * p < 0.05, ** p < 0.01, *** p < 0.001.
Fig 2: ROC curve analysis of galectin-1, HSI, FLI, and their combination diagnosis prediction of MASLD. The black dotted line represents the random classifier. The orange line, green line, blue line, and pink line represent the ROC curve of galectin-1, HSI, FLI, and their combination, respectively. The points above the black dotted line indicate a better probability than the random one. MASLD, metabolic dysfunction-associated steatotic liver disease; HSI, hepatic steatosis index; FLI, fatty liver index. AUC, area under the curve; ROC, receiver operating characteristic.
Fig 3: Regression analysis between HSI or FLI and serum galectin-1 levels using Pearson’s correlation analysis. (A) Galectin-1 was positively correlated with HSI. (B) Galectin-1 was positively correlated with FLI. r: regression coefficient. HSI, hepatic steatosis index; FLI, fatty liver index.
Fig 4: Differences in serum galectin-1, HSI and FLI between control and MASLD. (A) Serum galectin-1 differences between control and MASLD. (B) HSI differences between control and MASLD. (C) FLI differences between control and MASLD. Data represent the means ± SEM; *** p < 0.001. MASLD, metabolic-associated steatotic liver disease; HSI, hepatic steatosis index; FLI, fatty liver index.
Supplier Page from Thermo Fisher Scientific for Human Galectin-1 ELISA Kit